Summary of Guidelines for Managing Histoplasmosis among People Living with HIV

Freddy Perez; Diego H Caceres; Nathan Ford; Giovanni Ravasi; Beatriz L Gomez; Alessandro C Pasqualotto; Paul Hine; Antoine A Adenis; Mathieu Nacher; Tom Chiller; John Baddley; For The Guideline Development Group For Diagnosing And Managing Disseminated Histoplasmosis Among People Living With Hiv

doi:10.3390/jof7020134

Summary of Guidelines for Managing Histoplasmosis among People Living with HIV

Título traducido de la contribución: Resumen de directrices para el tratamiento de la histoplasmosis entre personas que viven con el VIH

Freddy Perez
, Diego H Caceres
, Nathan Ford
, Giovanni Ravasi
, Beatriz L Gomez
, Alessandro C Pasqualotto
, Paul Hine
, Antoine A Adenis
, Mathieu Nacher
, Tom Chiller
, John Baddley
, For The Guideline Development Group For Diagnosing And Managing Disseminated Histoplasmosis Among People Living With Hiv

Producción científica: Contribución a revista › Artículo de Investigación › revisión exhaustiva

35 Citas (Scopus)

Resumen

La histoplasmosis es una infección fúngica oportunista frecuente en personas que viven con VIH (PVVIH), asociada cada año a un total del 5% al 15% de las muertes relacionadas con el SIDA en esta población. En 2020, se publicaron las primeras directrices mundiales para el diagnóstico y tratamiento de la histoplasmosis diseminada entre personas que viven con el VIH. Este documento recomienda (1) la detección de antígenos circulantes de Histoplasma como prueba de laboratorio recomendada para diagnosticar la histoplasmosis entre las personas que viven con el VIH; (2) el uso de anfotericina liposomal para la terapia de inducción en enfermedades graves o moderadamente graves, seguida de una terapia de mantenimiento con itraconazol durante 12 meses; se podría considerar una terapia de mantenimiento más corta si el paciente está clínicamente estable y si el estado inmunológico ha mejorado; (3) inicio de la terapia antirretroviral lo antes posible en pacientes con histoplasmosis sin afectación del sistema nervioso central; y (4) que para el tratamiento de la coinfección con histoplasmosis y tuberculosis (TB), el tratamiento de la tuberculosis debe iniciarse de acuerdo con las pautas de tratamiento de la Organización Mundial de la Salud. Se requiere una educación sanitaria adecuada de los proveedores, supervisión de apoyo y orientación política para la atención de las personas que viven con el VIH.

Título traducido de la contribución	Resumen de directrices para el tratamiento de la histoplasmosis entre personas que viven con el VIH
Idioma original	Inglés estadounidense
Publicación	Journal of Fungi
Volumen	7
N.º	2
DOI	https://doi.org/10.3390/jof7020134
Estado	Publicada - feb. 12 2021

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Áreas temáticas de ASJC Scopus

Microbiología (médica)

Acceder al documento

10.3390/jof7020134

Citar esto

Perez, F., Caceres, D. H., Ford, N., Ravasi, G., Gomez, B. L., Pasqualotto, A. C., Hine, P., Adenis, A. A., Nacher, M., Chiller, T., Baddley, J., & For The Guideline Development Group For Diagnosing And Managing Disseminated Histoplasmosis Among People Living With Hiv (2021). Summary of Guidelines for Managing Histoplasmosis among People Living with HIV. Journal of Fungi, 7(2). https://doi.org/10.3390/jof7020134

@article{0aaed14ebb6a4ca3ad28026ba82f608a,

title = "Summary of Guidelines for Managing Histoplasmosis among People Living with HIV",

abstract = "Histoplasmosis is a frequent fungal opportunistic infection in people living with HIV (PLHIV), associated every year to a total of 5\% to 15\% of AIDS-related deaths among this population. In 2020, the first global guidelines for diagnosing and managing disseminated histoplasmosis among PLHIV was published. This document recommends (1) detection of circulating Histoplasma antigens as the recommended laboratory assay to diagnose histoplasmosis among PLHIV; (2) the use of liposomal amphotericin for induction therapy in severe or moderately severe disease, followed by a maintenance therapy with itraconazole for 12 months; a shorter maintenance therapy could be considered if the patient is clinically stable and if immune status has improved; (3) antiretroviral therapy initiation as soon as possible among patients with histoplasmosis without involvement of central nervous system; and (4) that for the treatment of co-infection with histoplasmosis and tuberculosis (TB), treatment of TB should be initiated according to the World Health Organization treatment guidelines. Appropriate health education of providers, supportive supervision, and policy guidance for the care of PLHIV are required.",

author = "Freddy Perez and Caceres, \{Diego H\} and Nathan Ford and Giovanni Ravasi and Gomez, \{Beatriz L\} and Pasqualotto, \{Alessandro C\} and Paul Hine and Adenis, \{Antoine A\} and Mathieu Nacher and Tom Chiller and John Baddley and \{For The Guideline Development Group For Diagnosing And Managing Disseminated Histoplasmosis Among People Living With Hiv\}",

year = "2021",

month = feb,

day = "12",

doi = "10.3390/jof7020134",

language = "English (US)",

volume = "7",

journal = "Journal of Fungi",

issn = "2309-608X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

Perez, F, Caceres, DH, Ford, N, Ravasi, G, Gomez, BL, Pasqualotto, AC, Hine, P, Adenis, AA, Nacher, M, Chiller, T, Baddley, J & For The Guideline Development Group For Diagnosing And Managing Disseminated Histoplasmosis Among People Living With Hiv 2021, 'Summary of Guidelines for Managing Histoplasmosis among People Living with HIV', Journal of Fungi, vol. 7, n.º 2. https://doi.org/10.3390/jof7020134

TY - JOUR

T1 - Summary of Guidelines for Managing Histoplasmosis among People Living with HIV

AU - Perez, Freddy

AU - Caceres, Diego H

AU - Ford, Nathan

AU - Ravasi, Giovanni

AU - Gomez, Beatriz L

AU - Pasqualotto, Alessandro C

AU - Hine, Paul

AU - Adenis, Antoine A

AU - Nacher, Mathieu

AU - Chiller, Tom

AU - Baddley, John

AU - For The Guideline Development Group For Diagnosing And Managing Disseminated Histoplasmosis Among People Living With Hiv, null

PY - 2021/2/12

Y1 - 2021/2/12

N2 - Histoplasmosis is a frequent fungal opportunistic infection in people living with HIV (PLHIV), associated every year to a total of 5% to 15% of AIDS-related deaths among this population. In 2020, the first global guidelines for diagnosing and managing disseminated histoplasmosis among PLHIV was published. This document recommends (1) detection of circulating Histoplasma antigens as the recommended laboratory assay to diagnose histoplasmosis among PLHIV; (2) the use of liposomal amphotericin for induction therapy in severe or moderately severe disease, followed by a maintenance therapy with itraconazole for 12 months; a shorter maintenance therapy could be considered if the patient is clinically stable and if immune status has improved; (3) antiretroviral therapy initiation as soon as possible among patients with histoplasmosis without involvement of central nervous system; and (4) that for the treatment of co-infection with histoplasmosis and tuberculosis (TB), treatment of TB should be initiated according to the World Health Organization treatment guidelines. Appropriate health education of providers, supportive supervision, and policy guidance for the care of PLHIV are required.

AB - Histoplasmosis is a frequent fungal opportunistic infection in people living with HIV (PLHIV), associated every year to a total of 5% to 15% of AIDS-related deaths among this population. In 2020, the first global guidelines for diagnosing and managing disseminated histoplasmosis among PLHIV was published. This document recommends (1) detection of circulating Histoplasma antigens as the recommended laboratory assay to diagnose histoplasmosis among PLHIV; (2) the use of liposomal amphotericin for induction therapy in severe or moderately severe disease, followed by a maintenance therapy with itraconazole for 12 months; a shorter maintenance therapy could be considered if the patient is clinically stable and if immune status has improved; (3) antiretroviral therapy initiation as soon as possible among patients with histoplasmosis without involvement of central nervous system; and (4) that for the treatment of co-infection with histoplasmosis and tuberculosis (TB), treatment of TB should be initiated according to the World Health Organization treatment guidelines. Appropriate health education of providers, supportive supervision, and policy guidance for the care of PLHIV are required.

U2 - 10.3390/jof7020134

DO - 10.3390/jof7020134

M3 - Research Article

C2 - 33673384

SN - 2309-608X

VL - 7

JO - Journal of Fungi

JF - Journal of Fungi

IS - 2

ER -

Summary of Guidelines for Managing Histoplasmosis among People Living with HIV

Resumen

ODS de las Naciones Unidas

Áreas temáticas de ASJC Scopus

Acceder al documento

Huella

Citar esto